On February 29, 2024, Canaccord Genuity analyst William Plovanic reiterated his Buy recommendation on Inari Medical (NASDAQ:NARI) while adjusting the price target from $79 to $75. This change reflects Plovanic’s assessment of the company’s performance and valuation.
Analyst coverage for Inari Medical includes not only William J. Plovanic from Canaccord Genuity but also Matt Taylor from Jefferies and analysts from Morgan Stanley. The consistent coverage and recommendations from these analysts offer valuable insights into how the market views Inari Medical’s stock.
During the recent earnings call for Q4 2023, Inari Medical announced record revenue growth driven by its core business strength, expanding therapies portfolio, and international expansion efforts. The company reported over $132 million in revenue for the fourth quarter and more than $493 million for the full year, marking a 29% growth. Despite the adjustment in the price target, this strong financial performance aligns with Plovanic’s Buy recommendation.
Inari Medical’s future prospects continue to look promising, as evidenced by the decision to maintain a Buy rating while lowering the price target. This indicates a positive outlook on the company’s trajectory, taking into consideration various financial and market factors.
NARI Stock Shows Positive Momentum with 3.37% Increase – What Investors Need to Know
On February 29, 2024, NARI stock showed some positive momentum as it closed the trading day with a 3.37% increase in price. The stock closed at $58.27, marking a $1.90 increase from the previous market close. Additionally, in after-hours trading, NARI stock continued to rise, gaining an additional $0.63.
Investors should consider these factors when evaluating NARI stock as an investment opportunity. While short-term gains are promising, the stock’s position relative to its historical performance and moving averages suggests that caution may be warranted.
As always, it is important for investors to conduct thorough research and analysis before making any investment decisions. Keeping an eye on market trends, company news, and financial indicators can help investors make informed choices about their investment portfolios.
NARI Stock Analysis: Mixed Performances in Revenue and Net Income for Q4 2023
On February 29, 2024, NARI stock experienced mixed performances based on its financial data. The company reported a total revenue of $383.47 million over the past year, which represented a 38.45% increase compared to the previous year. Additionally, the total revenue for the last quarter was $126.37 million, showing a 6.19% increase from the previous quarter.
NARI’s net income for the past year was -$29.27 million, indicating a significant decrease of 397.43% compared to the previous year. On a positive note, the net income for the last quarter improved to $3.16 million, representing a 51.65% increase from the previous quarter.
The earnings per share (EPS) for the past year were -$0.55, reflecting a decrease of 412.94% compared to the previous year. In contrast, the EPS for the last quarter improved to $0.05, showing a 51.69% increase from the previous quarter.
Overall, NARI stock showed improvements in revenue and net income compared to the previous quarter, but significant declines in these metrics were observed when compared to the previous year. Investors may want to closely monitor the company’s financial performance and future outlook to make informed decisions regarding their investment in NARI stock.
